Luca Valenti, Ahmad Al‐Serri, Ann K. Daly, Enrico Galmozzi, Raffaela Rametta, Paola Dongiovanni, Valerio Nobili, Enrico Mozzi, Giancarlo Roviaro, Ester Vanni, Elisabetta Bugianesi, Marco Maggioni, Anna Ludovica Fracanzani, Silvia Fargion, Christopher P.
Ian N. Hines – 26 March 2010
Pietro E. Majno, Gilles Mentha, Vincenzo Mazzaferro – 26 March 2010
Paul Feuerstadt, Ari L. Bunim, Heriberto Garcia, Jordan J. Karlitz, Hatef Massoumi, Amar J. Thosani, Andrew Pellecchia, Allan W. Wolkoff, Paul J. Gaglio, John F. Reinus – 26 March 2010 – Randomized controlled trials of hepatitis C virus (HCV) therapy with pegylated interferon and ribavirin have demonstrated sustained viral response rates (SVRs) of 54%‐63% (efficacy). Treatment results in clinical practice (effectiveness) may not be equivalent.
Heping Yang, Kwangsuk Ko, Meng Xia, Tony W.H. Li, Pilsoo Oh, Jiaping Li, Shelly C. Lu – 26 March 2010 – We previously showed that hepatic expression of glutathione (GSH) synthetic enzymes and GSH levels fell 2 weeks after bile duct ligation (BDL) in mice. This correlated with a switch in nuclear anti‐oxidant response element (ARE) binding activity from nuclear factor erythroid 2–related factor 2 (Nrf2) to c–avian musculoaponeurotic fibrosarcoma (c‐Maf)/V‐maf musculoaponeurotic fibrosarcoma oncogene homolog G (MafG).
Nicole K. Paulk, Karsten Wursthorn, Zhongya Wang, Milton J. Finegold, Mark A. Kay, Markus Grompe – 26 March 2010 – Adeno‐associated virus (AAV) vectors are ideal for performing gene repair due to their ability to target multiple different genomic loci, low immunogenicity, capability to achieve targeted and stable expression through integration, and low mutagenic and oncogenic potential. However, many handicaps to gene repair therapy remain. Most notable is the low frequency of correction in vivo. To date, this frequency is too low to be of therapeutic value for any disease.
Silvia Fargion, Luca Valenti, Anna Ludovica Fracanzani – 26 March 2010
Jesper B. Andersen, Roberto Loi, Andrea Perra, Valentina M. Factor, Giovanna M. Ledda‐Columbano, Amedeo Columbano, Snorri S. Thorgeirsson – 26 March 2010 – Human hepatocellular carcinoma (HCC) is a heterogeneous disease of distinct clinical subgroups. A principal source of tumor heterogeneity may be cell type of origin, which in liver includes hepatocyte or adult stem/progenitor cells. To address this issue, we investigated the molecular mechanisms underlying the fate of the enzyme‐altered preneoplastic lesions in the resistant hepatocyte (RH) model.
Dong‐Jiang Tang, Sui‐Sui Dong, Ning‐Fang Ma, Dan Xie, Leilei Chen, Li Fu, Sze Hang Lau, Yan Li, Yan Li, Xin‐Yuan Guan – 26 March 2010 – A high incidence of tumor recurrence and metastasis has been reported in hepatocellular carcinoma (HCC) patients; however, the underlying molecular mechanisms are largely unknown. In the present study a novel metastasis‐related gene, eukaryotic initiation factor 5A2 (EIF5A2), was characterized for its role in HCC metastasis and underlying molecular mechanisms.